New drug combo shows promise for slowing kidney disease

NCT ID NCT05856760

Completed Disease control Sponsor: Travere Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding a new medication called sparsentan could help adults with IgA nephropathy (IgAN), a kidney disease, when they were already taking standard treatments. Researchers followed 48 participants for 28 weeks to see if the combination was safe and could reduce protein in their urine, which indicates kidney damage. The goal was to see if this approach could help slow disease progression in people at risk of kidney failure.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Travere Investigation Site

Clifton Park, New York, 12065, United States
Travere Investigational Site

Birmingham, Alabama, 35233, United States
Travere Investigational Site

Chula Vista, California, 91910, United States
Travere Investigational Site

Garden Grove, California, 92844, United States
Travere Investigational Site

Glendale, California, 91206, United States
Travere Investigational Site

Denver, Colorado, 80230, United States
Travere Investigational Site

Boise, Idaho, 83706, United States
Travere Investigational Site

Chubbuck, Idaho, 83202, United States
Travere Investigational Site

Idaho Falls, Idaho, 83404, United States
Travere Investigational Site

Chicago, Illinois, 60611, United States
Travere Investigational Site

Evergreen Park, Illinois, 60805, United States
Travere Investigational Site

Fort Wayne, Indiana, 46804, United States
Travere Investigational Site

Kansas City, Kansas, 66160, United States
Travere Investigational Site

Louisville, Kentucky, 40205, United States
Travere Investigational Site

Shreveport, Louisiana, 71101, United States
Travere Investigational Site

Albuquerque, New Mexico, 87109, United States
Travere Investigational Site

Fresh Meadows, New York, 11365, United States
Travere Investigational Site

New York, New York, 10013, United States
Travere Investigational Site

Jacksonville, North Carolina, 28546, United States
Travere Investigational Site

New Bern, North Carolina, 28562, United States
Travere Investigational Site

Columbus, Ohio, 43210, United States
Travere Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Travere Investigational Site

Columbia, South Carolina, 29203, United States
Travere Investigational Site

Dallas, Texas, 75230, United States
Travere Investigational Site

Dallas, Texas, 75246, United States
Travere Investigational Site

Hong Kong, Hong Kong
Travere Investigational Site

Kowloon, Hong Kong
Travere Investigational Site

Shatin, Hong Kong
Travere Investigational Site

Sheung Wan, Hong Kong
Travere Investigational Site

Tsuen Wan, Hong Kong

Conditions

Explore the condition pages connected to this study.

IMMUNOGLOBULIN A NEPHROPATHY